Postoperative chemotherapy on placental site trophoblastic tumor in early stage: analysis of 60 cases.

Abstract

PURPOSE OF INVESTIGATION:

To review the literature of placental site trophoblastic tumor (PSTT) and explore the effect of postoperative chemotherapy in patients with Stage I.

MATERIALS AND METHODS:

The authors searched literature on Medline, Excerpta Medica Database (EMBASE), and other resources using the keywords "placental site trophoblastic tumor" and "PSTT" from 1981 ito 2014.

RESULTS:

A total number of 60 patients with Stage I disease were identified, and the presentation, treatment, tumor response, disease status, and follow-up were retrieved and reviewed. According to the authors' knowledge, 725 cases associated with PSTT have been reported in 29 nations/areas since 1981. In this series, the probability of overall survival at ten years in the group of surgery alone and postoperative chemotherapy were 96.7% and 79.1% (p = 0.199), and recurrence-free survival rates were 91.8% and 63.3%, respectively.

CONCLUSION:

The benefit from postoperative chemotherapy is still equivocal. There is a need for scrupulousness before adding postoperative chemotherapy.

• Authors: J C Nie, G H Chen, A Q Yan, X S Liu
• Journal: European journal of gynaecological oncology (Eur J Gynaecol Oncol) Vol. 38 Issue 3 Pg. 431-440 ( 2017) ISSN: 0392-2936 [Print] Singapore
• PMID: 29693886 (Publication Type: Journal Article)

Topics

• Adolescent
• Adult
• Combined Modality Therapy
• Female
• Humans
• Middle Aged
• Neoplasm Staging
• Pregnancy
• Trophoblastic Tumor, Placental Site (drug therapy, mortality, pathology)
• Uterine Neoplasms (drug therapy, mortality, pathology)
• Young Adult